erdafitinib has been researched along with Carcinoma--Hepatocellular* in 2 studies
1 review(s) available for erdafitinib and Carcinoma--Hepatocellular
| Article | Year |
|---|---|
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19 (FGF19) signaling through fibroblast growth factor receptor 4 (FGFR4) has been identified as an oncogenic driver for a subset of patients with HCC. FGFR4 is therefore a promising target for the treatment of HCC harboring aberrant FGF19-FGFR4 signaling, and several FGFR4 inhibitors have advanced to clinical trial. In this review, we summarize the latest developments in FGFR4 inhibitors, including the known pharmacophores, their binding mode, selectivity, and clinical implications, as well as the optimization strategy of introducing an acrylamide into a known pan-FGFR inhibitor targeting Cys552 of FGFR4 to provide selective covalent FGFR4 inhibitors. Topics: Binding Sites; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction | 2019 |
1 other study(ies) available for erdafitinib and Carcinoma--Hepatocellular
| Article | Year |
|---|---|
Discovery of 1,6-Naphthyridin-2(1
Fibroblast growth factor receptor 4 (FGFR4) has been identified as a potential target due to its transmission of the FGF19 signaling pathway, which is critical to hepatocellular carcinoma (HCC). Therefore, focusing on the specific Cys552 of FGFR4 subtype, we designed and synthesized a novel family of 1,6-naphthyridin-2(1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Fibroblast Growth Factors; Humans; Liver Neoplasms; Naphthyridines; Receptor, Fibroblast Growth Factor, Type 4 | 2022 |